N. Ghilezan

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial

Thomas Brodowicz, Maciej Krzakowski, Matjaž Zwitter et al. · Lung Cancer · 2006 · 322 citations

Medicine, Cancer Management, Phase Iii Trial +6

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer

G Brufman, E Colajori, N. Ghilezan et al. · Annals of Oncology · 1997 · 79 citations · Full text

Metastatic Breast Cancer, Oncology, Breast Oncology +8

Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial

George Plataniotis, M.A. Theofanopoulou, Anna Kalogera‐Fountzila et al. · International Journal of Radiation Oncology*Biology*Physics · 2004 · 70 citations

Adaptive Radiotherapy, Tumor Volumetry, Radiation Therapy +10

Gemcitabine, Epirubicin, and Paclitaxel Versus Fluorouracil, Epirubicin, and Cyclophosphamide As First-Line Chemotherapy in Metastatic Breast Cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial

Christoph Zielinski, S. Beslija, Zrinka Mršić-Krmpotić et al. · Journal of Clinical Oncology · 2005 · 63 citations · Full text

Capecitabine as salvage treatment in relapsed nasopharyngeal carcinoma: a phase II study.

E. Ciuleanu, A Irimie, Tudor–Eliade Ciuleanu et al. · PubMed · 2008 · 40 citations